EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY-NC 4.0

Confirmed Worsening of Health‐Related Quality of Life to Monitor Long‐Term MS Disease Progression: A Longitudinal Analysis From the Swiss Multiple Sclerosis Registry

Stefania Iaquinto iD, Benjamin Victor Ineichen, Mina Stanikić iD, Jens Kuhle, Christian Philipp Kamm, Pasquale Calabrese, Patrick Roth, Claudia Baum, Chiara Zecca iD, Claudio Gobbi iD, Özgür Yaldizli iD, Milo Alan Puhan und 2 weitere

European Journal of Neurology · 2025

DOI: 10.1111/ene.70230 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Stefania Iaquinto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Disease Progression, Quality of Life, Multiple Sclerosis, Patient Reported Outcome Measures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Schweizerische Multiple Sklerose Gesellschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Monitoring multiple sclerosis (MS) progression traditionally relies on clinical measures, which may overlook symptoms affecting quality of life. Incorporating patient‐reported outcomes could improve the understanding of disease worsening.

Objective

To evaluate an EQ‐5D‐based algorithm for detecting disease worsening and compare it with EDSS worsening.

Methods

We analyzed longitudinal EQ‐5D and EDSS data from the Swiss MS Registry. EQ‐5D worsening was defined as a sustained decline over two assessments; EDSS worsening followed established clinical criteria. Time to confirmed worsening was assessed using Kaplan–Meier curves and Cox regression. Patterns in 12 self‐reported symptoms were examined using descriptive statistics and logistic regression.

Results

By year four, 4.5% experienced EQ‐5D worsening, while 15.8% experienced EDSS worsening. Faster time to EQ‐5D worsening was associated with walking aids or higher BMI at baseline. Conversely, faster time to EDSS worsening was associated with male sex, progressive MS, or spasms as the first symptom. Symptom frequency was higher in the EQ‐5D worsening group, with pain and depression independently associated, while no symptoms were associated with EDSS worsening.

Discussion

While EQ‐5D worsening does not serve as an early clinical marker of disease progression, it may complement EDSS by capturing additional aspects of disease progression, particularly symptoms impacting HRQoL, that are not reflected in EDSS progression. Long‐term HRQoL monitoring alongside traditional measures may improve MS progression assessment and patient‐centered care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease ProgressionQuality of LifeMultiple SclerosisPatient Reported Outcome MeasuresSymptom AssessmentLongitudinal StudiesRegistriesSwitzerlandKaplan-Meier EstimateProportional Hazards ModelsLogistic ModelsAlgorithmsHumansMaleFemaleAdultMiddle AgedReproducibility of Results

Stichwörter der Autor:innen

EQ‐5Ddisease progressionhealth‐related quality of lifemultiple sclerosisoutcome measurement

Autor:innen und Institutionen

  • Department of Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
  • Department of Clinical Research, University of Bern, Bern, Switzerland.
  • Institute for Implementation Science in Health Care, University of Zurich, Zurich, Switzerland.
  • Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Neurology Clinic and Policlinic, Department of Head, Spine and Neuromedicine, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Clinical Research and Biomedical Engineering, Univ…
  • Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland.

ORCID-Profile: Stefania Iaquinto, Mina Stanikić, Chiara Zecca, Claudio Gobbi, Özgür Yaldizli

Förderung

  • Schweizerische Multiple Sklerose Gesellschaft

Zitieren

APA

Iaquinto, S., Ineichen, B. V., Stanikić, M., Kuhle, J., Kamm, C. P., Calabrese, P., Roth, P., Baum, C., Zecca, C., Gobbi, C., Yaldizli, Ö., Puhan, M. A., von Wyl, V., & Swiss Multiple Sclerosis Registry (2025). Confirmed Worsening of Health‐Related Quality of Life to Monitor Long‐Term MS Disease Progression: A Longitudinal Analysis From the Swiss Multiple Sclerosis Registry. European Journal of Neurology. https://doi.org/10.1111/ene.70230

Vancouver

Iaquinto S, Ineichen BV, Stanikić M, Kuhle J, Kamm CP, Calabrese P, et al. Confirmed Worsening of Health‐Related Quality of Life to Monitor Long‐Term MS Disease Progression: A Longitudinal Analysis From the Swiss Multiple Sclerosis Registry. European Journal of Neurology. 2025. doi:10.1111/ene.70230

BibTeX
@article{Iaquinto2025,
  author = {Iaquinto, Stefania and Ineichen, Benjamin Victor and Stanikić, Mina and Kuhle, Jens and Kamm, Christian Philipp and Calabrese, Pasquale and Roth, Patrick and Baum, Claudia and Zecca, Chiara and Gobbi, Claudio and Yaldizli, Özgür and Puhan, Milo Alan and von Wyl, Viktor and Swiss Multiple Sclerosis Registry, Swiss Multiple Sclerosis Registry},
  title = {Confirmed Worsening of Health‐Related Quality of Life to Monitor Long‐Term MS Disease Progression: A Longitudinal Analysis From the Swiss Multiple Sclerosis Registry},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70230}
}
Kostenlos starten →